TREA

97097081 - TCR2 THERAPEUTICS

Follow

Information

  • Trademark
  • 97097081
  • Serial Number
    97097081
  • Filing Date
    October 28, 2021
    3 years ago
  • Transaction Date
    December 11, 2023
    a year ago
  • Status Date
    December 11, 2023
    a year ago
  • Published for Opposition Date
    September 13, 2022
    2 years ago
  • Location Date
    November 08, 2022
    2 years ago
  • Status Code
    606
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    BECKER, JOSEPH RAPHAEL
  • Attorney Docket Number
    48538-TM1005
    Attorney Name
    Brandon P. Leahy
    Law Office Assigned Location Code
    M80
  • Owners
Information
Mark Drawing Code
5000
Mark Identification
TCR2 THERAPEUTICS
Case File Statements
  • DM0000: The mark consists of the stylized letters TCR and stylized number 2 above the stylized word THERAPEUTICS.
  • GS0051: Pharmaceutical preparations, namely, therapeutic cells, therapeutic proteins and therapeutic nucleic acids for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; pharmaceutical preparations for human use, namely, biotherapeutics, medicines, and therapeutics, namely, pharmaceutical polypeptides, pharmaceutical antibodies, pharmaceutical nucleic acids, polypeptide-based therapeutics, cell-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics for the treatment and prevention of cancer, inflammation and inflammatory diseases
  • PM0001: TCR TWO THERAPEUTICS
  • D10000: "TCR" and "THERAPEUTICS"
  • GS0421: Scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics; providing information on the subject of scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics
Case File Event Statements
  • 12/11/2023 - a year ago
    18 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Type: MAB6
  • 12/11/2023 - a year ago
    17 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6
  • 4/6/2023 - a year ago
    16 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 4/4/2023 - a year ago
    15 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 4/4/2023 - a year ago
    14 - SOU EXTENSION 1 FILED Type: EXT1
  • 4/4/2023 - a year ago
    13 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 11/8/2022 - 2 years ago
    12 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 9/13/2022 - 2 years ago
    11 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 9/13/2022 - 2 years ago
    10 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/24/2022 - 2 years ago
    9 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 8/10/2022 - 2 years ago
    8 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 8/10/2022 - 2 years ago
    7 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 8/10/2022 - 2 years ago
    6 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 8/10/2022 - 2 years ago
    5 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 8/10/2022 - 2 years ago
    4 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 8/8/2022 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/9/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 11/1/2021 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP